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A pool of 38 pan-African Centres of Excellence (CoEs) in health innovation has been selected and recognized by
the African Network for Drugs and Diagnostics Innovation (ANDI), through a competitive criteria based process. The
process identified a number of opportunities and challenges for health R&D and innovation in the continent: i) it
provides a direct evidence for the existence of innovation capability that can be leveraged to fill specific gaps in
the continent; ii) it revealed a research and financing pattern that is largely fragmented and uncoordinated, and
iii) it highlights the most frequent funders of health research in the continent. The CoEs are envisioned as an
innovative network of public and private institutions with a critical mass of expertise and resources to support
projects and a variety of activities for capacity building and scientific exchange, including hosting fellows, trainees,
scientists on sabbaticals and exchange with other African and non-African institutions.Introduction
The African continent bears the greatest burden of dis-
ease in the world today [1,2], but it has no mechanism
to ensure sustainable access to the health tools needed
by its people. Investment in health research and
innovation is a major factor in overcoming the high dis-
ease burden in the developing world especially Africa
[3-5]. A number of international and pan-African
reports and actions such as the Commission on Health
Research for Development [6], the Accra Plan of Action
[7], the Abuja declaration of 2001 by African leaders [8],
and a number of African Ministerial Declarations [9,10],
have stressed the need to invest in health and R&D cap-
acity for diseases that are predominant in developing* Correspondence: nwakas@who.int; nwakas@andifrica.org
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reproduction in any medium, provided the orcountries especially Africa [3,11]. The global strategy
and plan of action on public health innovation and intel-
lectual property (GSPOA) approved through World
Health Assembly resolutions also underlines the need to
invest in R&D innovation and capacity building in devel-
oping countries [4,12]. Although meeting the necessary
health and health R&D investment targets in Africa
remains a challenge for most African countries and de-
velopment partners, there are promising signs of im-
provement. Some African countries such as South
Africa, Kenya and Uganda are committing about 1% of
their gross domestic product (GDP) to R&D activities
[13], while development partners are increasingly dis-
cussing ways to enhance support for research and cap-
acity building in Africa [4,7].
Despite these developments, the current funding
streams for health research in Africa are still fragmented
and characterized by a number of small and short term
grants that are not always contributing to long-term de-
velopment of the health research system [14,15] and itLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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can lead to biased research agendas towards donor
interests in certain countries, activities or specific dis-
eases [16-18].
In addition, there is a lack of reliable data on capacity
for health research as well as limited knowledge about
where the real bottlenecks are, further underlining the
need for more institutional, systems and capacity evalu-
ation [15]. These observations sometimes paint a pes-
simistic view about the prospects of implementing a
robust health products R&D in Africa. Indeed, new data
are now emerging on the available capacity in the con-
tinent and how this capacity can be leveraged to contrib-
ute in solving Africa’s health challenges. The mapping of
the health R&D landscape in Africa, implemented in the
course of the development of the African Network for
Drug and Diagnostics Innovation (ANDI, www.andi-
africa.org), suggests that capacity for product R&D
and innovation exists in the continent [3,19-21]. How-
ever, this capacity is not effectively utilized to fill gaps
and solve Africa’s health problems due to the lack of
collaboration within Africa, lack of sustainable fund-
ing and coordination of existing research efforts as
well as governance and other issues. Other reports
have also reached similar conclusions [22-24].Figure 1 Continental mapping of applications received from the call
sub-regional and national coverage of applications submitted in response
colour are all countries from which at least one application was submitted
African Development Bank definition (http://www.afdb.org/en/countries/). O
applications in each region, for example, Egypt in Northern Africa, Kenya an
Africa, Nigeria in Western Africa and Cameroon in Central Africa.Another recent report has stressed that the current
global funding arrangements for public health need to
go beyond provision of treatments, but should also focus
on building requisite health research and development
infrastructure in the African continent [13]. The report
argues that this will position African institutions to take
advantage of not only globally available health technolo-
gies and products, but also invest in research institutions
that are both knowledge-based and oriented towards
product development. Despite these technical, policy
and political reports, little has materialized in terms of
structured implementation of concrete health innovation
activities in Africa, and existing capacity is not always
leveraged to support health research and development
to generate health products and evidence for policy.
As part of the implementation of ANDI activities and
consistent with its vision to leverage available capacity in
the continent, we initiated the identification and recog-
nition of African institutions with capacity in the various
areas of the health product innovation value chain, in-
cluding basic research, discovery, development, manu-
facturing and commercialization. We sought to evaluate
the capacity, competency and funding of African institu-
tions through a transparent workflow guided by a set of
criteria and review process. The goal was to identify afor Centers of Excellence. This figure represents the Continental,
to the call for Centres of Excellence by ANDI. Represented in gold
and sub-regional grouping of countries was done accordingly to the
ne or two countries per region are responsible for the bulk of
d Uganda in Eastern Africa, Republic of South Africa from Southern
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health innovation with necessary capacity and infrastruc-
ture to support the implementation of projects and cap-
acity building in the continent. We describe the process
that led to the identification of 38 Centres of Excellence
in health innovation, and how these centres will contrib-
ute to achieving the ANDI vision of creating a sustain-
able platform for health innovation in Africa and
providing solutions to the continents health challenges.
Methods
Call for Centres of Excellence (CoEs) and response
The identification of potential centers of excellence was
implemented through an open call for applications [25].
Considering the different languages in Africa, the call
was prepared in both English and French, and broadly
publicized at relevant meetings in Africa and overseas,
various websites as well as through mailing lists, e-mails
and advertisement in a major scientific journal. At the
deadline of the call, 117 applications from institutions
across Africa were received (Figure 1).
Some of the 117 applications requested to be consid-
ered as centers of excellence in multiple competency
areas, thereby making the number of applications based
on competencies to be 132. The country distribution, re-
gional spread and the various competencies across the
product R&D value chain for the applications received
are shown on Table 1 and Figure 1. The geographic
spread of CoE applications across the different African
countries and regions, demonstrates the pan African sig-
nificance of this process. Applications were received
from 26 countries covering the five regions of Africa.
Similar numbers of applications were received from
Southern, Eastern and Western Africa as follows, 25.6%,
25.6% and 24.0% respectively; while Northern and Cen-
tral Africa had lesser numbers with 15.4% and 9.4% of
the applications respectively (Figure 1). The fact that
about 50% of African countries were represented in this
first call for CoE is indicative of the level of interest in
the process within the continent. We believe that with
broader advertisement of future calls for application,
many more countries will be covered.
Review and assessment of applications for CoEs
The 117 applications were evaluated using a 4-step re-
view process based on defined qualitative and quantita-
tive criteria [25]. These criteria include: availability of
infrastructure and equipment for the specific research
area; number of staff working in the area; track record of
the technical staff; productivity of the institution over a
period of time as measured by publications in peer
reviewed journals or patents or products discovered or
developed; availability and access to good communica-
tion tools including internet, website, telephone etc.,as well as financial sustainability of the institution as
evidenced by budget allocation over a 3-year period
(2008–2010).
The review of the applications for CoEs was imple-
mented in different phases as follows:
1) Phase 1 review involved assessment by peers: this
involved heads of the applying institutions in a manner
that avoided conflict of interest or having peers review
their own applications or applications from
collaborating institutions. This first review helped to
isolate the 76 applications identified as scoring at least
70 out of 100 points which would enter the second
reviewing phase.
2) Phase 2 review involved evaluation by the ANDI
Scientific and Technical Advisory Committee (STAC),
which is an important part of ANDI’s structure [3].
Shortlisted applications were sent electronically to
STAC members for review and scoring without
revealing the scores from phase 1. Following the
feedback from this review all scores from STAC were
tallied alongside the scores from the phase 1 review and
the overall score sheet was sent back to STAC
electronically in preparation for phase 3.
3) 1Phase 3 review involved a face to face meeting of
STAC to discuss the 70 applications that scored over 70
points out of a total of 100 points after second review,
with the objective of recommending those that met
most of the criteria, scoring at least 80 points, as
potential CoE. This resulted in the identification of 33
centers, which entered phase 4.
4) Phase 4 review involved verifications of the information
presented by short listed 33 centers. Following extensive
electronic assessment of these centers including referee
reports and interviews, a total of 32 centers were
recommended by STAC as ANDI CoE in health
innovation in Africa. At this stage, STAC agreed to
further assess applications from manufacturers based on
additional criteria established to determine their
manufacturing status, including any national or
international certification by relevant authorities that
the centers may have attained. Evaluation of this
information resulted in accepting an additional six CoEs
from the manufacturers sector making the total
number of CoEs 38 (Table 2). The STAC further
recommended that the designation of CoE be granted
by ANDI for a period of 5 years with a mid-term review
that will involve site visits and evaluation of CoEs using
an outcome metrics. This outcome metrics is being
developed in consultation with the CoEs. Furthermore,
new calls for CoEs will be launched intermittently by
ANDI to identify new Centres that meet the CoE
criteria or fill a specific gap that has been identified
by ANDI.
Table 1 ANDI call for Center of Excellence results














Algeria 2 (3) North - - - - - - 1 2
Egypt 12 (13) 2 5 1 - - 1 2 2
Morocco 2 (4) - 2 - - - - - 2
Tunisia 2 - 1 - - - - 1 -
Ethiopia 2 East - - 1 - - - 1 -
Kenya 13 2 1 2 2 2 1 1 2
Sudan 1 - 1 - - - - - -
Tanzania 3 1 1 - - - 1 - -
Uganda 11 (12) 1 1 1 - 4 1 2 2
Botswana 1 South - - - - - 1 - -
Mauritius 1 - 1 - - - - - -
Mozambique 1 - - - - 1 - - -
South Africa 24 8 9 - 1 1 1 - 4
Zambia 1 - - - - - - 1 -
Zimbabwe 2 (4) 1 2 - - 1 - - -
Benin 1 West - - - - - - - 1
Burkina Faso 3 - 2 - - 1 - - -
Côte d'Ivoire 1 - - - - - - - 1
Ghana 5 (6) 1 2 1 - 1 1 - -
Mali 1 - - - - 1 - - -
Nigeria 16 (21) - 7 8 2 2 - - 2
Senegal 1 - - 1 - - - - -
Cameroon 6 (7) Central 1 3 2 - - - - 1
Chad 1 (2) - - - - - - 1 1
Democratic Republic of Congo 3 - 1 - - - - 1 1
Republic of Congo 1 - - - - - - - 1
Total 117 (132) 18 39 17 5 14 7 11 22
1 Activities related to evaluation of new or already registered products or available technology including implementation research, or diagnostics performance evaluation etc.
2 Epidemiology, Health Systems, Ethics, IP management, Knowledge & data management.
This table shows specific number of applications received by countries and regions as well as functional R&D competency areas that were covered by application received. Total number of applications per
competency area received is 132, which is higher than the total number of individual applications which is 117. The reason for this is that some applications did apply to be considered for two or more competency
areas within their single application. Numbers in the Applications column represent the number of individual application per country (in bold, 117 in total) and the number of competency areas covered by the
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Table 2 Selected ANDI Centers of Excellence in Health Innovation (Continued)
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Table 2 Selected ANDI Centers of Excellence in Health Innovation (Continued)
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he 38 successful ANDI Centres of Excellence in health innovation following a 4 step review process. The names of the CoE which reflects the competency of the
stitution as well as the contact information of head of the CoE and website are indicated.
he contact person is either the institutional head (in bold) or the lead responsible for the proposed center of excellence.

























TAnalysis of financing data from CoE
The applying institutions were requested to provide in-
formation on funding for their research and sources of
the funding for the period 2008–2010, detailing local or
external sources of funds. Local sources refer to all funds
coming from within the institution or the country where
the institution is located, while external funding refers to
funds from outside the country or the continent, both
from public and private sources.
From the 117 applications received, 93 applications
(including those from the manufacturing sector) hadfinancial data for the three-year period while data was
available for either one or two years for the rest of
the applications. Following the removal of duplicate
funding information from institutions applying for
more than one centre of excellence, a total of 88
applications were analysed. All the applications pro-
vided specific names of funding agencies on an an-
nual basis, however, the exact amount provided by
each funder or donor were not included. Therefore it
is important to stress that the ranking of funding
agencies or donors presented here does not represent
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frequency of appearance within all the applications
received by ANDI.
All financing information were collated and analysed
as follows:
i) Determination of the annual and cumulative funding
over the three year period: This was done by
collating the total annual research funds from
applications, both with and without the applications
from manufacturers.
ii) Funding sources: A listing of all the donor agencies
named in each of the applications as funding the
research performed was compiled with the number
of times they were mentioned in the applications.
Results and discussion
Successful Centres of Excellence (CoE)
The review process resulted in the identification of 32
institutions (Figure 2) plus 6 manufacturers, spread
across the five African regions, that met the ANDI cri-
teria for CoE. It should be mentioned that recognizing
the manufacturers should in no way be seen as an ANDI
endorsement of these manufacturers‘ capacity to produce
under GMP or relevant national and international stan-
dards. Rather, the goal is to identify manufacturers that
have met criteria established by ANDI, to enable them to
participate in relevant ANDI network activities, includingFigure 2 Spread of successful Center of Excellence by region. This figu
Excellence, without the recognized Manufacturing CoE. The strong represe
manufacturers not represented in diagram, 2 came from Southern Africa an
centers from these regions as 16 and 8 respectively. Western Africa and No
centres from these regions as 7 and 5 respectively.product development projects, public-private partner-
ships, training, etc.
The list of all the CoEs with their areas of competency
and contact information are presented in Table 2. CoEs
were announced during the 4th ANDI stakeholders
meeting in Addis Ababa, Ethiopia from 24th to 27th
October, 2011 [26], while the finalisation of the evalu-
ation of the manufacturing CoEs followed the meeting.
A significant number of the successful CoEs are located
in Southern Africa (16 in number), particularly in Re-
public of South Africa with a total of 12 centers, which
is the highest number seen per country. The Eastern and
Western African regions followed Southern Africa with
8 and 7 centers respectively, predominantly located in
Kenya, Uganda, Nigeria and Ghana. Northern Africa
recorded 5 CoEs of which 4 came from Egypt and one
from Tunisian. It is not clear why more applications
were not received from Northern Africa especially with
the increasing role of Northern African region in R&D
exemplified by a recent announcement from Algerian
government for increased funding for research [27]. This
will probably improve with better communication of fu-
ture calls for applications in the Northern African re-
gion. The Central African region had the lowest number
of accredited CoEs with only 2 centers located in
Cameroon. The result also highlights the need for more
investment and capacity building in the Central African
region, particularly the Francophone countries [3,20].re represents the regional spread of primary 32 identified Center of
ntation of Southern African region should be noted. Note that of the 6
d another 2 from Eastern Africa making the total number of successful
rthern Africa had 1 manufacturer each making the total number of
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has the full capacity for all the components of the pro-
ducts value chain (Table 1), reinforcing the value of con-
tinental network with the critical mass of institutions
with capacity spread across the innovation value chain
[3,20,28]. With regards to academic-industry or public-
private partnerships, about 38% of the CoEs claim to
having active partnerships with industry. These types ofFigure 3 Health R&D funding between 2008 and 2010. Graph A data d
of the application. On the average, 65% of R&D budget is coming from ext
budget for manufacturers that responded to the ANDI call is added to the
average 57% when the budget of manufacturers is included.public - private partnerships will further be strengthened
through an integrated CoE framework programme that
supports capacity building and project implementation,
as further elaborated below.
Funding of health R&D in Africa
The total annual research funds from all applications ex-
cluding and including manufacturers are shown inoes not include the budget for manufacturing centers received as part
ernal funding sources outside the African continent. In graph B, the
R&D budget on graph A. Note the increased internal funding to an
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show a steady and modest increase in annual funding
over the three year period largely due to increased fund-
ing from external sources, while funding from within
12Africa decreased from 39% to 32% (Figure 3A). This
suggests that most African countries and governments
were unable to sustain investment in health R&D in the
period and the hope is that this trend will now change.
However, when the budget for the manufacturers are
included in the analysis, the internal/external ratio was
reversed with more funding coming from internal
sources up to an average of 57% over the three year
period (Figure 3B). This suggests that funding from both
private and public sectors in Africa, largely targets
manufacturing activities. Although a steady increase in
funding for health innovation was observed over a three
year period (Figure 3), our data highlights a number of
challenges as well as opportunities for African health
innovation financing. The annual budget of departments
or units, within African institutions range from five hun-
dred US Dollars ($500) to thirty five million US Dollars
($35 million) with a mean value of $1.49 million. The
relatively low budget of most African institutions com-
pared to other parts of world, could explain some of the
challenges faced by African institutions in translating
their research findings into usable health products. ItFigure 4 Top 21 most frequent donors of health R&D in Africa. The zo
the donors that were most frequently mentioned in the applications analy
type of funders as listed in Table 3. EU/EC (European Union and European
(World Health Organization), TDR (Special Programme for Research and Tra
International Development ), EDCTP (European and Developing Countries C
(GlaxoSmithKline), SANRF (South African National Research Foundation), CD
Forschungsgeminschaft Germany), WT (Wellcome Trust), DFID (UK Departm
New Diagnostics), ADW (Academy for Developing World), IAEA (Internatio
Technologies in Health), MRC -UK (Medical Research Council UK).also underlines the need for a better coordination of
funding and access to grants in Africa.
A listing of all the funders/donor agencies named in
each of the applications is presented in Additional file 1:
Table S1. The data shows that a total of 266 different
donor agencies supported research of the applying Afri-
can institutions over the three year period. Out of these
266 agencies, only 27 donors were identified as African
based. This financing information made it possible to
further determine the 21 most frequently mentioned
funding agencies in all the applications (Figure 4). The
National Research Foundations (NRF) of South Africa
was identified as the only African institution that made
the list of 21 most frequent health research funders in
Africa [29]. The fact that NRF has also been highlighted
as the biggest research funding agency in Africa in the
area of natural and physical sciences corroborates our
data [11]. Accordingly, the Republic of South Africa also
featured as one of the top 10 funders of research in Af-
rica by country when all sources of funding are consid-
ered (Table 3). It is therefore not surprising to have
identified the highest number of successful Centers of
Excellence as coming from South Africa. Our data is in
agreement with a trend in R&D across Africa in which
institutions from countries and regions that invest more
resources, as measured by the percentage of GDPomed out bar graph on the right hand corner of the figure highlights
zed for ANDI centers of excellence. Bar colors represent the different
Commission, B&MGF (Bill and Melinda Gates Foundation), WHO
ining in Tropical Diseases, USAID (United States Agency for
linical Trial Partnership), NIHUS (National Institute of Health US), GSK
C (Centre for Disease Control US), DFG (Deutsche
ent for international Development ), FIND (Foundation for Innovative
nal Atomic Energy Agency), PATH (Program for Appropriate
Table 3 Summary of all donor information by country and other categories
Countries Public donors Private and philanthropic donors TOTAL FREQUENCY
NA A/H IN NPO IO FREQUENCY IP PF FREQUENCY
United States of America 51 19 3 20 93 11 40 51 144
Republic of South Africa 33 2 4 39 4 5 9 48
United Kingdom 16 4 1 21 12 13 25 46
Switzerland 9 3 12 24 5 8 13 37
Germany 17 3 1 21 2 3 5 26
France 3 4 5 12 6 6 18
Italy 9 1 10 1 1 11
Sweden 9 2 11 0 11
Canada 6 3 9 1 1 10
Kenya 4 1 3 8 1 1 9
The Netherlands 2 2 2 1 7 1 1 2 9
Spain 7 1 8 0 8
Ghana 3 1 2 6 0 6
Egypt 2 2 4 1 1 5
Nigeria 1 1 2 2 1 3 5
Tanzania 1 1 3 3 4
Australia 1 1 2 1 1 3
Ireland 3 3 0 3
Belgium 1 1 2 0 2
Burkina Faso 1 1 1 1 2
Czech Republic 2 2 0 2
Finland 2 2 0 2
Japan 0 2 2 2
Norway 2 2 0 2
Senegal 1 1 1 1 2
Cuba 1 1 0 1
Denmark 1 1 0 1
Israel 0 1 1 1
New Zeeland 0 1 1 1
Republic of Saudi Arabia 1 1 0 1
Slovakia 1 1 0 1
Uganda 1 1 0 1
United Arabic Emirates 1 1 0 1
Others
United Nations 66 66 66
European Union 46 46 46
Development Banks 9 9 9
African Union 4 4 4
TOTAL 186 51 27 33 125 422 49 79 128 550
This table show the entire data set of the different types of donors mentioned in the applications based on country and other categories such international
organizational and regional organizations. NA mean National Agency, A/H =Academics & Hospitals, IN = International Network, NPO=Non-Profit Organization,
IO = International Organization, IP = Industry Partner, PF = Private Foundation.
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chance of qualifying as CoE. Countries such as Kenya,
Uganda and South Africa have averaged about 1% of
GDP investment in R&D [6,30]. These numberssubstantiate previous publications and collaboration
patterns in Africa [20].
In the context of external donors, European and North
American countries and agencies (including public,
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in health research in Africa (Table 3). Finally, it is import-
ant to highlight the absence of emerging economies,
namely China, India, South Korea and Brazil, from the list
of donor countries, suggesting the need to engage these
countries and to reinforce south-south partnerships with
Africa.
As expressed above, the key measure of investment
in R&D is the percentage of a country or region’s
GDP devoted to such activities. This is often termed
gross expenditure on research and development -
GERD [11,13]. Available data show that Africa as a
whole accounted for only 0.9% share of world GERD
in 2007 while Asia had 32.2%, Oceania 1.6%, Latin
America and the Caribbean 3%, Europe 27.4% and
North America 38% [31]. On the other hand, some
recent economic analyses have highlighted the eco-
nomic growth potential of Africa - the continent's
GDP rose by an average of 4.9% annually from 2000
to 2008, making it the world's third-fastest growing
region [32].For this growth to be sustained, signifi-
cant resources and efforts has to be invested in R&D
and innovation, including through support for strong
intra-African exchange and collaboration. Medical
research now dominate African research, having
overtaken agricultural research, which was the lead-
ing field in the 1990s [13,24]. It is important there-
fore to intensify and leverage this existing health
R&D momentum to support collaboration among Af-
rican R&D institutions to develop the most needed
health products to address the continent's health
needs. This will also bring economic benefits includ-
ing human capital development, retention of health
researchers and experts and African integration. We
believe that a critical mass of CoEs in health
innovation in Africa, working collaboratively and
sharing information and know-how, would contribute
to achieving this goal through joint projects, net-
working, capacity building and training as well as
technology transfer and diffusion across the contin-
ent. Indeed, lessons learned from a number of inter-
national initiatives further illustrate the power of
organized centers of excellence [23,33-36]. For ex-
ample, Canada Network for Centres of Excellence,
has helped to turn Canadian research and entrepre-
neurial talent into economic and social benefits for
all Canadians by funding research partnerships be-
tween academia, industry, government, and not-for-
profit organizations [33].
The ANDI CoEs are envisioned as a network that
will bring African scientific and technical resources
together to build capacity, develop and diffuse
technology to address African's health challenges
in a significant way [3,25,37]. A detailed projectframework that defines how the ANDI COEs net-
work will achieve the desired objectives is being
finalised. For example, a structured pool of fellow-
ships and training across the continents can be
implemented through the CoE network, including
MSC, PhD, postdoctoral, vocational or technical
training as well as sabbatical for scientists from
other African institutions, who wish to spend time
at an ANDI CoE for specific training purpose. A
central capacity building fund can be established to
support qualifying candidates and African institu-
tions that aspire to become a CoE in a specific field.
Through this same mechanism, North–South and
South-South collaboration and exchange can be
enhanced. The CoE network can also support the
placement of external experts who wish to spend
time in an African CoE to support capacity building
of Africans and gain more experience in Africa. This
will include placement of experts from industry and
leading academic institutions and laboratories
abroad, who wish to support specific R&D, manage-
ment, regulatory training and other needs of the net-
work. Having said these, there are arguments for and
against, for example the concentration of research
funding in few institutions versus the distribution of
academic talent and research funding among univer-
sities [38]. Indeed, the goal of ANDI is not to focus
research funding on the CoEs but rather to use them
to support capacity building and create partnerships
to implement projects that come from a variety of
African institutions.
Conclusion
Our work has revealed the diversity and richness of
African institutions and their potential to support
coordinated projects and capacity building activities
in areas such as disease surveillance, epidemiology,
biotechnology, product development, manufacturing,
as well as the development or spin off platforms for
new biotechnology companies and agencies for
health innovation in Africa. We believe that a cred-
ible and sustainable solution to the health challenges
in Africa must leverage existing R&D, manufacturing
and commercialization capacity across the continent
to support integrated capacity utilization and eco-
nomic development [3,20,39]. Hopefully, our work
will encourage more funding for health R&D and
prevent the significant fragmentation of financing in
the continent. As a pan-African initiative focusing
on health R&D, promoting local manufacturing and
access to medicines, the ANDI initiative is in a good
position to contribute in the actualization of an inte-
grated and coordinated product R&D platform in the
African continent.
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names retrieved from the 117 applications received for the identification
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appearance, which means the number of times a particular donor is
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